Fuente:
Prohibición Partners
Lugar:
General
Report Contents
Jump to any section in the series
Introduction →
Definitions And Scope →
Executive Summary →
Key Trends →
Market Value →
Legislation and Regulation →
Consumer Attitudes →
Healthcare Providers’ Attitudes →
Spotlight On Health →
Psychedelics – Timeline of Key Developments →
Countries to Watch →
Psychedelic Profiles →
Key Psychedelics Deep Dive →
Other Psychedelics of Note →
Psychedelics as Medicine: Potential Therapies →
Psychedelics and Technology →
Psychedelics Per Country →
Psychedelics and The Law →
Patents and Intellectual Property →
Therapy Practitioners →
Psychedelic Research →
Glossary →
No matches. Try a different keyword.
This section provides a country-by-country overview of psychedelic medicine activity, including substances under investigation, the scale of clinical research, notable organisations, and the estimated valuation of psychedelic companies operating within each jurisdiction.
Australia
Psychedelic medicines studied: DMT, ketamine, N₂O, MDMA, psilocybin
Clinical trials: 2
Creso Pharma entered the psychedelic medicines industry in July 2021 through the acquisition of Canadian psychedelics company Halucenex Life Sciences. Mind Medicine Australia (MMA), a registered charity, supports clinical research into psychedelic-assisted therapies. The Psychae Institute is headquartered in Melbourne and has received AU$4.6 million in initial funding.
Estimated valuation of companies: $17m
Brazil
Psychedelic medicines studied: ayahuasca, DMT, ketamine, ibogaine, MDMA, psilocybin
Clinical trials: 3
Brain Institute at the Federal University of Rio Grande do Norte has conducted research into neural plasticity, inflammation and neurodegeneration triggered by 5-MeO-DMT. Núcleo de Estudos Interdisciplinares sobre Psicoativos focuses primarily on ayahuasca, its application and anthropological importance. The University of São Paulo hosted a clinical trial investigating ayahuasca’s antidepressant potential in 2015.
Canada
Psychedelic medicines studied: ayahuasca, ibogaine, ketamine, psilocybin
Clinical trials: 18
Braxia Scientific owns and operates multidisciplinary clinics, while Cybin Corp focuses on drug delivery systems and proprietary psychedelic derivatives. Havn Life Sciences became the first psychedelic company to list on Nasdaq’s Global Select Market. Numinus Wellness announced Health Canada approval to study MDMA for PTSD in July 2021. TheraPsil submitted a proposal for psilocybin regulation to Health Canada in August 2021.
Estimated valuation of companies: $2.1bn
China
Psychedelic medicines studied: ketamine, psilocybin
Clinical trials: 12
Zhejiang University School of Medicine identified anatomical and molecular targets of ketamine’s fast-acting antidepressant effects. M2BIO, a subsidiary of Wuhan General Group, is researching psilocybin-based therapies for mental health disorders and CBD products.
Denmark
Psychedelic medicines studied: psilocybin
Clinical trials: 3
Octarine Bio is backed by private investors and developed early-stage platforms expanding the chemical diversity of psychedelic derivatives.
Estimated valuation of companies: $6m
Germany
Psychedelic medicines studied: psilocybin, ketamine
Clinical trials: 1
Atai Life Sciences is a biotech company focusing on developing psychedelic medicines and is the largest publicly traded psychedelics company. MIND Foundation is a non-profit organisation advancing psychedelic research and therapy.
Estimated valuation of companies: $2.3bn
Ireland
Psychedelic medicines studied: 5-MeO-DMT
Clinical trials: 3
GH Research completed its phase I clinical trial in April 2021. Atai Life Sciences backed GH Research following a €27m funding round.
Estimated valuation of companies: $1bn
Netherlands
Psychedelic medicines studied: 5-MeO-DMT, MDMA, psilocybin
Clinical trials: 4
Blossom operates as a web platform providing insights on research, companies and regulatory attitudes. Synthesis Institute provides medically supervised psychedelic experiences and has raised over $4m.
Estimated valuation of companies: $8m
Spain
Psychedelic medicines studied: ibogaine, MDMA
Clinical trials: 3
ICEERS is a non-profit organisation dedicated to transforming society’s relationship with psychoactive plants through research and education.
Switzerland
Psychedelic medicines studied: ayahuasca, DMT, ketamine, LSD, MDMA, mescaline, psilocybin
Clinical trials: 36
Heffter Research Institute and University Hospital Basel have driven clinical research across multiple psychedelics, including altered states of consciousness and therapeutic applications.
United Kingdom
Psychedelic medicines studied: ibogaine, ketamine, MDMA, psilocybin
Clinical trials: 11
Awakn Life Sciences operates treatment clinics and conducts addiction research. Beckley Psytech is developing first- and second-generation psychedelic compounds. COMPASS Pathways is conducting large-scale clinical trials for psilocybin-assisted therapy.
Estimated valuation of companies: $1.8bn
United States
Psychedelic medicines studied: DMT, ibogaine, ketamine, kratom, LSD, MDMA, psilocybin, salvinorin A
Clinical trials: 171
Maya Health develops software platforms for psychedelic clinics. Journey Clinical supports mental health professionals integrating psychedelic medicine. Tactogen and TRIPP are developing next-generation compounds and immersive therapeutic tools. Wesana Health focuses on psychedelic compounds for traumatic brain injury and related conditions.
Estimated valuation of companies: $1.8bn
← Previous
Download report ↓
Next →
Prefer the full dataset? Download the complete report (PDF).
Download the full report
Enter your details to access the PDF instantly.
×
The post Psychedelics per Country: Research, Companies and Market Activity – PSYCH: The Psychedelics As Medicine Report 3rd Edition appeared first on Prohibition Partners.
